Anti Inflammatory News and Research

RSS

Anacor, Medicis collaborate to discover and develop boron-based treatment for acne

Anacor Pharmaceuticals, Inc. and Medicis Pharmaceutical Corporation today announced that the two companies have entered into a research and development agreement to discover and develop boron-based small molecule compounds directed against a target for the potential treatment of acne.

11 Feb 2011

Athersys' MultiStem cell therapy provides multiple benefits in preclinical models of ischemic stroke

Medical researchers from The University of Texas Health Science Center at Houston (UTHealth) presented new research results at the American Heart Association International Stroke Conference that demonstrated how MultiStem-, a novel stem cell therapy being developed by Athersys, Inc. provided multiple benefits when administered in preclinical models of ischemic stroke.

11 Feb 2011

Promedior initiates Phase 1b clinical study of PRM-151 in patients with IPF

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today that it has initiated a Phase 1b clinical study of PRM-151 to explore the safety, tolerability, pharmacokinetics, and phamacodynamics of PRM-151 in the treatment of patients with idiopathic pulmonary fibrosis.

11 Feb 2011

Cytomedix granted CE mark for Angel Blood Separation System and activAT Autologous Thrombin Processing Kit

Cytomedix, Inc. today announced that the Company has been issued a CE marking certification for its Angel® Whole Blood Separation System ("Angel") and its activAT® Autologous Thrombin Processing Kit ("activAT").

10 Feb 2011

Tart cherries can help athletes reduce muscle damage more quickly

Tart cherries could help athletes reduce muscle damage to recover faster from a tough workout, according to new research published in the American College of Sports Medicine's journal Medicine & Science in Sports & Exercise.

10 Feb 2011

Genmed announces Suprafen drug registration with Dutch MEB

Genmed Holding Corp. has announced its next generic drug registration. The Company will file it's dossier for the drug Suprafen, otherwise known as Ibuprofen, with the Dutch Medicines Evaluation Board in the coming months. Suprafen is a non-steroidal anti-inflammatory as well as an analgesic.

9 Feb 2011

Targacept initiates TC-6987 Phase 2 study in patients with asthma, Type 2 diabetes

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced the initiation of separate Phase 2 clinical studies of its product candidate TC-6987 in disorders characterized by inflammation, one in asthma and one in Type 2 diabetes.

9 Feb 2011

Transition reports second quarter 2011 net income of $24.28M vs. $6.05M net loss for second quarter 2010

Transition Therapeutics Inc., a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the quarter ended December 31, 2010.

8 Feb 2011

Patients receiving cancer treatment may experience skin, hair, nail problems

A cancer diagnosis and subsequent treatment, which commonly includes chemotherapy or radiation, can be taxing physically and emotionally on any patient. If that is not enough, dermatologists are cautioning patients receiving cancer treatment and cancer survivors that they may experience a host of skin, hair or nail problems as a direct result of their therapy that may require additional treatment by a dermatologist.

5 Feb 2011

Tips for women to ensure a healthy heart and a healthy vacation

Henrico County based Mondial Assistance, the largest travel insurance provider in the world, and the American Heart Association's (AHA) Mid-Atlantic chapter are teaming up for the 2011 Go Red for Women campaign and as part of the effort are offering these tips for women to ensure a healthy heart and a healthy vacation in 2011. Mondial Assistance is a "Healthy Lifestyle" Partner for this year's campaign.

5 Feb 2011

New data on CYTOMIMIC Technology's potential to stimulate tissue repair featured at 69th AAD

Johnson & Johnson Consumer Companies, Inc. today announced that its award-winning, breakthrough CYTOMIMIC™ Technology will be featured in a scientific poster at the 69th Annual Meeting of the American Academy of Dermatology (AAD), February 4-8, 2011, at the Ernest N. Morial Convention Center in New Orleans, LA.

5 Feb 2011

Anacor initiates dosing in AN2728 Phase 2b trial for psoriasis

Anacor Pharmaceuticals announced today that the first patient has been dosed in a Phase 2b trial of AN2728, a topical anti-inflammatory product candidate for the treatment of psoriasis. Psoriasis is a chronic inflammatory skin disease that affects approximately 7.5 million people in the United States and over 100 million people worldwide.

4 Feb 2011

Stem cells delivered intranasally improve motor function in Parkinson's disease

Stem cells, delivered intranasally, were found to substantially improve motor function in Parkinson's disease in a study co-authored by William H. Frey II, Ph.D, Director of the Alzheimer's Research Center, part of HealthPartners Research Foundation. Frey collaborated with Lusine Danielyan, MD, of University Hospital of Tubingen in Germany.

4 Feb 2011

Study: Pistachios may help reduce risk of heart disease

It's no coincidence that National Pistachio Day – February 26, 2011 – occurs during American Heart Month. Heart disease remains the leading cause of death in America, and promising nutrition research shows that pistachios are a heart healthy snack choice. In honor of American Heart Month, TheGreenNut.org is offering simple tips encouraging all Americans to go green for a healthy heart this February.

4 Feb 2011

Proper diagnosis and antibiotic treatment are the best way to prevent Lyme arthritis

Early, correct diagnosis is the best way to prevent the development of Lyme arthritis in individuals with the tick-borne illness, according to a paper published in the Journal of the American Academy of Orthopaedic Surgeons. In patients who do develop the condition, most cases can be treated successfully with antibiotics, the review found.

3 Feb 2011

Enrollment stopped in one of two global necitumumab Phase III studies in NSCLC

Eli Lilly and Company and Bristol-Myers Squibb Company announced today that they have stopped enrollment in one of their two global Phase III studies evaluating necitumumab, an investigational anti-cancer agent, as a first-line treatment for advanced non-small cell lung cancer (NSCLC).

3 Feb 2011

Harbor BioSciences announces publication of newly discovered anti-inflammatory steroids

Harbor BioSciences, a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today announced publication of newly discovered anti-inflammatory steroids naturally present in humans.

2 Feb 2011

Research identifies potential reversibility of chronic neurologic disability in stroke survivors

A breakthrough in stroke research identifying the potential reversibility of chronic neurologic disability in stroke survivors has published today. In the February 1, 2011 issue of the journal CNS Drugs the first human results of a new method of targeting chronic brain inflammation years after stroke are reported.

2 Feb 2011

VBL commences two studies to evaluate efficacy, safety of VB-111 in advanced cancers

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the initiation of two studies to further evaluate the efficacy and safety of VB-111 in advanced cancers.

31 Jan 2011

Etanercept can restore responsiveness to pain-relieving effects of morphine: Study

A drug called etanercept can restore responsiveness to the pain-relieving effects of morphine in rats that have developed morphine tolerance, reports a study in the February issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

29 Jan 2011

Anti Inflammatory News and Research

Anacor, Medicis collaborate to discover and develop boron-based treatment for acne

Athersys' MultiStem cell therapy provides multiple benefits in preclinical models of ischemic stroke

Promedior initiates Phase 1b clinical study of PRM-151 in patients with IPF

Cytomedix granted CE mark for Angel Blood Separation System and activAT Autologous Thrombin Processing Kit

Tart cherries can help athletes reduce muscle damage more quickly

Genmed announces Suprafen drug registration with Dutch MEB

Targacept initiates TC-6987 Phase 2 study in patients with asthma, Type 2 diabetes

Transition reports second quarter 2011 net income of $24.28M vs. $6.05M net loss for second quarter 2010

Patients receiving cancer treatment may experience skin, hair, nail problems

Tips for women to ensure a healthy heart and a healthy vacation

New data on CYTOMIMIC Technology's potential to stimulate tissue repair featured at 69th AAD

Anacor initiates dosing in AN2728 Phase 2b trial for psoriasis

Stem cells delivered intranasally improve motor function in Parkinson's disease

Study: Pistachios may help reduce risk of heart disease

Proper diagnosis and antibiotic treatment are the best way to prevent Lyme arthritis

Enrollment stopped in one of two global necitumumab Phase III studies in NSCLC

Harbor BioSciences announces publication of newly discovered anti-inflammatory steroids

Research identifies potential reversibility of chronic neurologic disability in stroke survivors

VBL commences two studies to evaluate efficacy, safety of VB-111 in advanced cancers

Etanercept can restore responsiveness to pain-relieving effects of morphine: Study

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News